

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Health Resources and Services Administration****White House Initiative on Asian Americans and Pacific Islanders, President's Advisory Commission; Notice of Meeting; Correction**

In **Federal Register** Document 00-11449 appearing on page 26219 in the issue for Friday, May 5, 2000, the following corrections have been made to the Notice of Meeting for the President's Advisory Commission. The room number for the meeting on May 17, 2000 has been changed from Room 800 of the Hubert H. Humphrey Building to the Stonehenge Room of the Hubert H. Humphrey Building. A time change has taken place for the meeting on May 19, 2000. The meeting will take place from 9:00 a.m.–1:00 p.m. Those are the only changes to be noted. All other information is correct as it appears.

An additional meeting has been scheduled and will take place on Thursday, May 18, 2000. This meeting will be open to the public. The meeting will be held on May 18, 2000 from 2:00 p.m.–5:00 p.m. in Room 800 of the Hubert H. Humphrey Building located at 200 Independence Avenue, SW, Washington, DC 20201.

Requests to address the Commission should be made in writing and should include the name, address, telephone number and business or professional affiliation of the interested party. Individuals or groups addressing similar issues are encouraged to combine comments and present through a single representative. The allocation of time for remarks may be adjusted to accommodate the level of expressed interest. Written requests should be faxed to (301) 443-0259. Anyone who has interest in attending any portion of the meetings or who requires additional information about the Commission should contact: Mr. Tyson Nakashima, Office of the White House Initiative on Asian Americans and Pacific Islanders, Parklawn Building, Room 10-42, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-2492. Anyone who requires special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mr. Nakashima no later than Tuesday, May 16, 2000.

Dated: May 11, 2000.

Jane M. Harrison,

Director, Division of Policy Review and Coordination.

[FR Doc. 00-12445 Filed 5-17-00; 8:45 am]

BILLING CODE 4160-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****Government-Owned Inventions; Availability for Licensing**

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Mutant Aequorea Victoria Fluorescent Proteins Having Increased Cellular Fluorescence

George N. Pavlakis, George A. Gaitanaris, Roland H. Stauber, John N. Vournakis (NCI)
U.S. Patent 6,027,881 issued 22 February 2000
Licensing Contact: Girish C. Barua; 301/406-7056 ext. 263; e-mail: gb18t@nih.gov

The Green Fluorescent Protein (GFP) from the jellyfish *Aequorea victoria* is rapidly becoming an important reporter molecule for monitoring gene expression *in vivo*, *in situ* and *in real time*. GFP can be used to tag proteins, cellular compartments, or cells, and has found many uses in the study of biological processes. Unlike other bioluminescent reporters, GFP fluoresces in the absence of any other proteins, substrates, or cofactors. Improved signal to noise ratio is important for several applications using GFP. We have generated GFP mutants that increase the fluorescent signal by at least tenfold over the wild-type GFP in mammalian cells. These mutants emit either green or blue light, detectable when single copy genes are inserted into the cell.

Method for Refolding Recombinant Endostatin

Dong Xie, Paul Grulich, John W. Erickson (NCI)
DHHS Reference No. E-260-99/0 filed 18 Feb 2000
Licensing Contact: Richard Rodriguez; 301/496-7056 ext. 287; e-mail rr154Z@nih.gov

Endostatin is a naturally occurring collagen-derived fragment that has been the subject of intense interest due to its reported anti-tumor and anti-metastatic properties. Endostatin's exact mode of action is unknown, and a detailed analysis of this mode of action has been hampered by the inability to consistently produce large quantities of refolded recombinant endostatin. While endostatin can be recombinantly produced, the isolated protein is found in an unfolded state. Thus a need exists to produce recombinant endostatin in a biologically active form for continuing clinical development and studying specific motifs or structures associated with endostatin which may be responsible for its anti-angiogenic/metastatic properties. The current invention comprises a method of renaturing endostatin comprising contacting unfolded endostatin with an effective amount of cyclodextrin in an aqueous environment buffered at a neutral or acidic pH.

CpG Oligodeoxynucleotides Used To Improve Human Immune Responses

Dennis Klinman, Daniela Verthelyi, Kenji Ishii (FDA)
DHHS Reference No. E-078-00/0 filed 14 Jan 2000
Licensing Contact: Peter Soukas; 301-496-7056, ext. 268; e-mail: ps193c@nih.gov

This invention concerns immune-activating oligonucleotides containing CpG motifs. Although it is known that certain CpG sequences can induce responses from human immune system cells, individual subjects show considerable heterogeneity in their response to different CpG sequences. These different responses make it difficult to induce a therapeutic immune response in all members of a diverse population using a single CpG sequence, even if such a sequence is repeated in a CpG oligonucleotide. The inventors have found that a broad-based immunomodulatory response can be generated in a wide cross-section of subjects by using a mixture of multiple different CpG motifs. The mixture of oligodeoxynucleotides of the present invention can either be mixtures of different oligodeoxynucleotides expressing different CpG motif is or a